Upstream Bio Inc.
Overview
Upstream Bio is developing treatments for inflammatory diseases, focusing on severe respiratory diseases, and is advancing verekitug, an antagonist targeting the TSLP receptor, currently in clinical development.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Upstream Bio Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.